Sinovac Biotech P/S 2024

Sinovac Biotech Aktienanalyse

What does Sinovac Biotech do?

Sinovac Biotech Ltd is a Chinese biopharmaceutical company specializing in researching, developing, manufacturing, and marketing vaccines for infectious diseases. The company was founded in 2001 and is headquartered in Beijing. The history of Sinovac began with the establishment of the company by CEO Dr. Yin Weidong. Dr. Yin was an experienced researcher in the field of vaccine development and had previously worked at the China Academy of Medical Sciences. His vision was to establish a company that produces innovative vaccines against severe and potentially life-threatening diseases. Sinovac's business model is based on the discovery and development of vaccines against viral diseases. The company works closely with leading research and development institutes in China to develop its products. It has several production facilities in China that meet the highest international standards and ensure excellent quality assurance. Sinovac specializes in various areas, including influenza, hepatitis, pneumococcal, rotavirus, rubella, and SARS vaccines. It is the only company in China authorized to manufacture and sell the inactivated seasonal flu vaccine used in China every year. Furthermore, Sinovac has successfully developed an inactivated hepatitis A vaccine and an inactivated Sinovac RS vaccine, which uses a unique technology to protect the vaccine against rejection reactions and adverse side effects. One of Sinovac's most significant products is the Sinovac CoronaVac vaccine, which is being used worldwide under emergency authorization by the World Health Organization to combat the Covid-19 pandemic. The vaccine has been successfully deployed in many countries worldwide and has shown high effectiveness against the virus. Sinovac also has a long history of collaborating with international organizations and governments to provide vaccines for the prevention of infectious diseases. It is an important supplier of vaccines to the Chinese government and has successfully developed vaccines against the swine flu epidemic and enterovirus, which are widespread in China. Overall, Sinovac is strongly committed to research, development, and manufacturing innovation. The company has taken a leadership role in combating infectious diseases in China and globally, and has an impressive track record in the development and production of vaccines at the highest level. Sinovac Biotech ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/S Details

Decoding Sinovac Biotech's P/S Ratio

Sinovac Biotech's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.

Year-to-Year Comparison

Comparing Sinovac Biotech's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.

Impact on Investments

The P/S ratio is instrumental for investors evaluating Sinovac Biotech's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.

Interpreting P/S Ratio Fluctuations

Variations in Sinovac Biotech’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.

Frequently Asked Questions about Sinovac Biotech Stock

What is the price-to-earnings ratio of Sinovac Biotech?

The price-earnings ratio of Sinovac Biotech is currently 1.44.

How has the price-earnings ratio of Sinovac Biotech changed compared to last year?

The price-to-earnings ratio of Sinovac Biotech has increased by 193.88% increased compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Sinovac Biotech high compared to other companies?

Yes, the price-to-earnings ratio of Sinovac Biotech is high compared to other companies.

How does an increase in the price-earnings ratio of Sinovac Biotech affect the company?

An increase in the price-earnings ratio of Sinovac Biotech would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Sinovac Biotech affect the company?

A decrease in the price-earnings ratio of Sinovac Biotech would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Sinovac Biotech?

Some factors that influence the price-earnings ratio of Sinovac Biotech are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Sinovac Biotech pay?

Over the past 12 months, Sinovac Biotech paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Sinovac Biotech is expected to pay a dividend of 0 USD.

What is the dividend yield of Sinovac Biotech?

The current dividend yield of Sinovac Biotech is .

When does Sinovac Biotech pay dividends?

Sinovac Biotech pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Sinovac Biotech?

Sinovac Biotech paid dividends every year for the past 0 years.

What is the dividend of Sinovac Biotech?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Sinovac Biotech located?

Sinovac Biotech is assigned to the 'Health' sector.

Wann musste ich die Aktien von Sinovac Biotech kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Sinovac Biotech from 6/26/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 6/26/2024.

When did Sinovac Biotech pay the last dividend?

The last dividend was paid out on 6/26/2024.

What was the dividend of Sinovac Biotech in the year 2023?

In the year 2023, Sinovac Biotech distributed 0 USD as dividends.

In which currency does Sinovac Biotech pay out the dividend?

The dividends of Sinovac Biotech are distributed in USD.